stockmarketproxy
/
ELANNYSE SEC EDGAR

Elanco Animal Health Inc

Pharmaceutical Preparations·INDIANAPOLIS, IN·FY end 12/31·CIK 1739104
OverviewFinancialsCompensationGovernanceInsidersFilings

Board of Directors

9 members · 8 independent · FY 2025
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Kapila AnandDirector8y72AuditNCG$297,507
Paul HerendeenDirector6y70AuditFinance Strategy and Oversight$340,029
Michael HarringtonDirector8y63AuditNCGFinance Strategy and Oversight$346,007
Lawrence KurziusChair8y68$480,007
Kirk McDonaldDirector7y59CompTechTech$350,007
Art GarciaDirector7y65AuditFinance Strategy and Oversight$330,007
Stacey MaDirector2y56CompTechTech$252,480
Denise Scots-KnightDirector7y66CompTechTech$330,007
Jeffrey SimmonsCEO and Director8y58Finance Strategy and Oversight

Risk-factor diff

FY 2025 10-K vs. FY 2024
+327 new301 removed

Net-new paragraphs in the most recent 10-K's Item 1A. Companies rarely add risk language without a real reason — additions here are often a leading signal of management concerns.

NEW · FY 2025

The following table provides a summary of cash flows from operating, investing and financing activities for the years ended December 31, 2025 and 2024:

NEW · FY 2025

Cash provided by operating activities increased $19 million compared to 2024. While net income was lower in 2025 than in 2024, the decrease was largely attributable to the prior year gain on our aqua business divestiture, for which the related cash proceeds were classified within investing activities, and increased restructuring charges due to our 2025 Restructuring Plan, the vast majority of which were either non-cash in nature or remain accrued as a liability as of December 31, 2025 (see

NEW · FY 2025

Note 5. Asset Impairment, Restructuring and Other Special Charges

NEW · FY 2025

to the consolidated financial statements for further information). Cash paid for interest was $90 million lower in 2025 than in 2024, while cash paid for taxes, which included cash payments related to the taxable gain on our 2024 aqua business divestiture, was $85 million higher in 2025 than in 2024.

NEW · FY 2025

Cash used for investing activities was $279 million for the year ended December 31, 2025, compared to cash provided by investing activities of $1,158 million

+ 25 more new paragraphs not shown

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.